Sentinel lymph node biopsy positivity in patients with acral lentiginous and other subtypes of cutaneous melanoma
JAMA — Cheraghlou S, Ugwu N, Girardi M, et al. | January 21, 2022
Researchers examined sentinel lymph node (SLN) positivity rate in the melanoma subtype acral lentiginous melanoma (ALM), a rare subtype of malignant melanoma typically occurring on the palmar and plantar surfaces. Further, they described the clinical stage-specific rates of SLN positivity for ALM based on the AJCC Cancer Staging Manual, 8th edition (AJCC-8).
From the National Cancer Database (NCDB), data of a total of 60,148 patients were included in this retrospective cohort study.
Findings revealed an independent association of ALM with an increased rate of SLN positivity; the estimated positivity rates were 18.39% and 39.53% for AJCC Cancer Staging Manual, 8th edition, clinical stage IB and II disease, respectively.
Based on the findings, they support encouraging sentinel lymph node biopsy for all patients with clinical stage IB and II ALM, and providing appropriate counseling to such patients concerning the higher regional metastatic risk of their cancers.